These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17453375)

  • 1. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
    Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
    Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
    Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
    Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
    Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
    Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
    Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of imatinib in unresectable hepatocellular carcinoma.
    Lin AY; Fisher GA; So S; Tang C; Levitt L
    Am J Clin Oncol; 2008 Feb; 31(1):84-8. PubMed ID: 18376233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
    Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
    Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of flutamide in the treatment of hepatocellular carcinoma.
    Chao Y; Chan WK; Huang YS; Teng HC; Wang SS; Lui WY; Whang-Peng J; Lee SD
    Cancer; 1996 Feb; 77(4):635-9. PubMed ID: 8616754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
    Smith SM; Grinblatt D; Johnson JL; Niedzwiecki D; Rizzieri D; Bartlett NL; Cheson BD;
    Br J Haematol; 2008 Feb; 140(3):313-9. PubMed ID: 18217897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J; Maisnar V
    Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
    Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
    Hsu WC; Chan SC; Ting LL; Chung NN; Wang PM; Ying KS; Shin JS; Chao CJ; Lin GD
    Jpn J Clin Oncol; 2006 Feb; 36(2):93-9. PubMed ID: 16517834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
    Vestermark LW; Larsen S; Lindeløv B; Bastholt L
    Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
    Shao YY; Lin ZZ; Hsu C; Lee KD; Hsiao CH; Lu YS; Huang CC; Shen YC; Hsu CH; Cheng AL
    Oncology; 2012; 82(1):59-66. PubMed ID: 22310088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
    Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
    Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.